Skip to main content

budesonide (Jorveza®)

 

Status: AWMSG assessment in progress

As maintenance therapy for eosinophilic esophagitis in adults (older than 18 years of age).

Medicine details

Medicine name budesonide (Jorveza®)
Formulation 0.5 mg and 1 mg orodispersible tablet
Reference number 4507
Indication

As above

Company Dr Falk Pharma UK Ltd
BNF chapter Gastro-intestinal system
Assessment type Limited
Status AWMSG assessment in progress
Scrutiny Panel meeting date 03/11/2025
LOWMAG meeting date 15/04/2026
AWMSG meeting date 20/05/2025
Date of issue 24/09/2020
Follow AWTTC: